Ptc Therapeutics (PTCT) Receivables (2013 - 2026)

Ptc Therapeutics' Receivables history runs 14 years deep, the most recent figure standing at $219.9 million for Q1 2026.

• On a quarterly basis, Receivables rose 4.48% year-over-year to $219.9 million in Q1 2026; TTM through Mar 2026 was $219.9 million, a 4.48% increase from a year earlier, with the FY2025 full-year figure at $181.6 million, up 14.55% from the prior year.
• Receivables grew to $219.9 million in Q1 2026 per PTCT's latest filing, from $181.6 million in the prior quarter.
• Across five years, Receivables topped out at $219.9 million in Q1 2026 and bottomed at $124.5 million in Q3 2022.
• The 5-year median for Receivables is $181.6 million (2025), against an average of $177.7 million.
• Across the five-year window, Receivables soared 72.51% in 2022 and dropped 1.69% in 2024, its largest moves.
• Year by year, Receivables stood at $155.6 million in 2022, then grew by 3.48% to $161.0 million in 2023, then declined by 1.53% to $158.6 million in 2024, then gained by 14.55% to $181.6 million in 2025, then gained by 21.09% to $219.9 million in 2026.
• Per Business Quant, the three latest PTCT Receivables figures stand at $219.9 million (Q1 2026), $181.6 million (Q4 2025), and $203.1 million (Q3 2025).